News >

FDA Approvals Represent New Wave of Progress in Advanced HCC

Caroline Seymour
Published: Monday, Apr 15, 2019

Benjamin Leon Musher, MD

Benjamin Leon Musher, MD

Until recently, sorafenib (Nexavar) was the only FDA-approved systemic therapy for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Now, lenvatinib (Lenvima), regorafenib (Stivarga), cabozantinib (Cabometyx), nivolumab (Opdivo), pembrolizumab (Keytruda), and ramucirumab (Cyramza) have been added to the paradigm for patients across a multitude of settings, explained Benjamin Leon Musher, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication